Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.92 USD | -3.06% | +4.36% | -33.21% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.21% | 144M | |
+9.56% | 115B | |
+13.29% | 107B | |
-13.58% | 22.31B | |
-3.58% | 21.6B | |
-5.71% | 18.23B | |
-38.57% | 17.62B | |
+7.78% | 14.26B | |
+34.44% | 12.37B | |
-26.99% | 8.28B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-13-2022 08